NeoChord, Inc.
Transforming Mitral Valve Repair
Transforming Mitral Valve Repair
NeoChord, Inc. is a pioneering medical technology company that is on a mission to revolutionize mitral valve repair for patients suffering from mitral valve regurgitation. Established in 2007, the company's flagship product, the NeoChord Artificial Chordae Delivery System, obtained CE market clearance in December 2012. The groundbreaking technology addresses a critical need in the biotechnology and healthcare industries. Recently, NeoChord secured a noteworthy $2.80M Convertible Note investment on 06 May 2021, signaling ongoing support and confidence in the company's innovative approach to mitral valve repair. As a United States-based company, NeoChord, Inc. has been attracting attention and investment within the healthcare sector, positioning itself at the forefront of transformative advancements in mitral valve treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | $2.80M | - | 06 May 2021 | |
| Funding Round | $4.13M | - | 09 Feb 2021 | |
| Venture Round | $4.45M | - | 06 Aug 2020 | |
| Venture Round | $3.77M | - | 29 Apr 2019 | |
| Series D | $7.00M | 1 |
|
24 Apr 2019 |
No recent news or press coverage available for NeoChord, Inc..
We care about your data, and we'd love to use cookies make your experience better.
